Plasma-derived therapies company Kedrion Biopharma announced on Tuesday that it will be honoured by Premier Inc, a technology-driven healthcare improvement company, during the annual Supplier Innovation Celebration at its 2026 Breakthroughs Conference and Exhibition.

The Innovation Celebration aims to recognise groundbreaking healthcare technologies launched throughout the year and highlight how these products help improve the health of communities.

Kedrion's QIVIGY was approved by the US Food and Drug Administration (FDA) in 2025 for the treatment of adults with primary humoral immunodeficiency (PI). It is also being studied across additional patient populations and indications.